Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 14
Submit an article Journal homepage
830
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma

Kishan K. Patela Department of Hematology/Oncology, Yale University School of Medicine, New Haven, CT, USAView further author information
,
Iris Isufia Department of Hematology/Oncology, Yale University School of Medicine, New Haven, CT, USAView further author information
,
Shalin Kotharia Department of Hematology/Oncology, Yale University School of Medicine, New Haven, CT, USAView further author information
,
Francine Fossa Department of Hematology/Oncology, Yale University School of Medicine, New Haven, CT, USAView further author information
&
Scott Huntingtona Department of Hematology/Oncology, Yale University School of Medicine, New Haven, CT, USA;b Yale Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, New Haven, CT, USACorrespondence[email protected]
View further author information
Pages 3387-3394 | Received 19 May 2020, Accepted 03 Aug 2020, Published online: 24 Aug 2020

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

R. Andrew Harkins & Christopher R. Flowers. (2020) How should clinicians interpret conflicting cost-effectiveness analyses for the treatment of lymphoma across nations and payer models?. Leukemia & Lymphoma 61:14, pages 3283-3286.
Read now

Articles from other publishers (2)

Swetha Kambhampati, Monica Saumoy, Yecheskel Schneider, Stacy Pak, Lihua Elizabeth Budde, Matthew G. Mei, Tanya Siddiqi, Leslie L. Popplewell, Yi-Ping Wen, Jasmine Zain, Stephen J. Forman, Larry W. Kwak, Steven T. Rosen, Alexey V. Danilov, Alex F. Herrera & Nikhil R. Thiruvengadam. (2022) Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma. Blood 140:25, pages 2697-2708.
Crossref
Leonard Jeff Harris, Kruti Patel & Michael Martin. (2020) Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. International Journal of Molecular Sciences 21:22, pages 8553.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.